To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay.
Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG (FL-MOG) or the short-length form (SL-MOG). The Abs were initially detected by Alexa Fluor goat anti-human IgG (H + L) and subsequently by Alexa Fluor mouse antibodies to human IgG1.
When tested at 1:20 dilution, 40/1,109 sera were positive for AQP4-Abs, 21 for SL-MOG, and 180 for FL-MOG. Only one of the 40 AQP4-Ab–positive sera was positive for SL-MOG-Abs, but 10 (25%) were positive for FL-MOG-Abs ( p = 0.0069). Of equal concern, 48% (42/88) of sera from controls (patients with epilepsy) were positive by FL-MOG assay. However, using an IgG1-specific secondary antibody, only 65/1,109 (5.8%) sera were positive on FL-MOG, and AQP4-Ab– positive and control sera were negative. IgM reactivity accounted for the remaining anti-human IgG (H + L) positivity toward FL-MOG. The clinical diagnoses were obtained in 33 FL-MOG–positive patients, blinded to the antibody data. IgG1-Abs to FL-MOG were associated with optic neuritis (n = 11), AQP4-seronegative neuromyelitis optica spectrum disorder (n = 4), and acute disseminated encephalomyelitis (n = 1). All 7 patients with probable multiple sclerosis (MS) were MOG-IgG1 negative.
ACTRIMS-CMSC (non-profit entity), Funding for travel and speaker honorarium.
(1) NIH NIAMSR03 AR061529 (PI O?Connor) 07/01/11? 06/30/14 (2)NIH-DFCI P01 AI045757(WUCHERPFENNIG)09/15/08 ? 08/31/13 (role, co-investigator) (3)NIH-NIAID U19 AI050864 9/1/10-8/31/12 (PI, O'CONNOR)
PLOS ONE, academic editor, 2012-Current Medicinal Chemistry, editorial board, 2006-2012 Autoimmune Diseases, 2012-2013
Dr. Reindl and Medical University of Innsbruck receive payments for antibody assays (AQP4 and antineuronal antibodies) and for AQP4 antibody validation experiments organized by Euroimmun.
Austrian Science Fund (FWF), grants W1206 and I916 Austrian Federal Ministry of Science grant ?BIG-WIG MS? Jubilaeumsfonds of the Austrian National Bank, grants 14158 and 15198
Charity: member of Medical Committee: Myaware ( ex. myasthenia gravis Association) 2013-
1 Use of LGI1 as an antigen in detection of autoantibodies 2. Use of GABAa gamma subunit in detection of autoantibodies (pending)
My department receives payment for running Diagnostic assays for a range of autoantibodies
Epilepsy research UK (ERUK)P1201 LANG: Established and novel cell-surface autoantibodies in adults with new-onset cryptogenic epilepsies
Use of LGI1 as an antigen in detection of autoantibodies (royalties) 2013-2014 ongoing
Dr. Misu has received speaker honoraria from Bayer Schering Pharma, Biogen Idec., and Mitsubishi Pharma.
Dr. Misu has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Kuraray Medical Co., The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma, and Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan.
Recieved funding for a trip and speaks from Biogen Idec Japan (2012-2014); Tanabe Mitsubishi (2012-2014); Novartis Pharma (2012-2014).
Serve as an editorial board member of Multiple Sclerosis International(2010-present).
Received grant support from LSI Medience Corporation (2012-2014).
UK advisory board participant: 1) Merck Serono 2) Bayer Schering Pharma 3) Biogen Idec 4) Teva Pharmaceutical Industries Ltd. 5) Novartis Pharmaceuticals UK Ltd. 6) Sanofi-Aventis 7) Alexion 7) Alexion
Support for attending ECTRIMS Merck Serono Novartis and Biogen idec Talks at sicentific meetings (majority have CME) Bayer schering, Biogen Idec, Merk Serono,
(1) ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.
In addition to advisory committees, consultant for: Ono Pharmaceuticals Ltd. Chugai Pharma Ltd. CI Consulting Biogen Idec GlaxoSmithKline
Donations to support local service development and research, none relevant to the current work: Bayer Schering Merke Serono Novartis
Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service
Serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Merck Serono, Alexion Pharmaceuticals, Medimmune and Medical Review.
has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co., Daiichi Sankyo, Nihon Pharmaceutical, and Cosmic Corporation
Serve as an editorial board member of Clinical and Experimental Neuroimmunology (2009-present) and a advisory board member of Sri Lanka journal of Neurology.
has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical,Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme Japan.
Funded as the primary (#26293205, 2016-2018) and secondary investigator (#22229008, 2010-2015) by the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan and as the secondary investigator by the Grants-in-Aid for Scientific Research from theMinistry of Health, Welfre and Labor of Japan (2010-present).
Occasional small honoraria, travel and speaker honoraria from Baxter International Inc and Biogen Inc
Hold patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG.
Royalties from Athena Diagnostics (MuSK assays). Royalties received from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010). System in Children (Mac Keith Press, 2010)
Consultancy with Athena Diagnostics for assessing their antibody assays ?5K pa. Ended 2014.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.